Novartis AG Common Stock (NY:NVS)

140.42 -0.58 (-0.41%)

Delayed Quote Updated: 9:40 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novartis AG Common Stock

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

59 60 Next >

Elsevier Launches New Pharmapendium, Empowering Pharma Companies to Bring Novel Drugs to Market Faster and Increase Success of Regulatory Submissions

October 10, 2023

London, United Kingdom--(Newsfile Corp. - October 10, 2023) - Elsevier, a global leader in information and data analytics, has launched...

Via Newsfile

Topics Animal Testing

3 Artificial Intelligence Stocks That Could Outperform the ‘Godfather of AI’ ↗

October 09, 2023

These are the AI stocks to buy and hold for multibagger returns in the next 24 months, as they represent quality growth companies.

Via InvestorPlace

Topics Artificial Intelligence

Eli Lilly, McKesson, Novartis Flash Promising Chart Action

October 09, 2023

Eli Lilly, McKesson, and Novartis are catching investors' attention with promising chart patterns and revenue growth, signaling potential buying opportunities.

Via MarketBeat

Protecting Cannabis Products & More: New Sustainable Child-Resistant Packaging By Dymapak ↗

October 05, 2023

Dymapak, a global manufacturer specializing in innovative child-resistant packaging solutions for various industries, has introduced a child-resistant Consumer Packaged Goods (CPG) packaging...

Via Benzinga

Topics Cannabis

Why Cal-Maine Foods Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session ↗

October 04, 2023

Gainers Gaucho Group Holdings, Inc. (NASDAQ: VINO) jumped 95.2% to $3.7280. Gaucho Group is planning to list two of its retail properties in Argentina, in San Rafael and Cordoba, for sale, priced at $2...

Via Benzinga

Novartis Shares Decline As Spin Off Sandoz's Market Debut Falls Short of Expected Valuation ↗

October 04, 2023

Sandoz Group AG (OTC: SDZNY) (OTC: SDZXF) enters a new era as a standalone player in generic and biosimilar medicines.

Via Benzinga

SDZNY Stock: 7 Things to Know as Novartis Spinoff Sandoz Starts Trading Today ↗

October 04, 2023

Sandoz (SDZNY) stock is a hot topic among traders on Wednesday as the company starts trading after a spinoff from Novartis.

Via InvestorPlace

Cancer Drug Maker 3D Medicines Inc. Trading Higher After Company Announces It Will Repurchase Up To 10% Of Outstanding Shares ↗

October 04, 2023

3D Medicines Inc. was trading 7.2% higher in the Hong Kong Wednesday morning session at HK$5.53 after the company announced that it is buying back up to 10% of its own stock.

Via Benzinga

Cal-Maine Foods, A10 Networks And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session ↗

October 04, 2023

U.S. stock futures traded mixed this morning on Wednesday. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Novartis Mulls Divesting Some Assets Of Radiopharma Unit In Strategic Shift ↗

October 03, 2023

Swiss pharmaceutical giant Novartis AG (NYSE: NVS) is reportedly contemplating selling sections of radiopharmaceuticals company Advanced Accelerator Applications to align with the company's strategy...

Via Benzinga

Drugmakers Agree To Participate For Medicare Drug Price Negotiation With Biden Administration ↗

October 03, 2023

All ten manufacturers of the first drugs selected for Medicare price negotiations will be participating, the White House said, even though many of them are suing the administration

Via Benzinga

Novartis' Investigational Therapy Shows Promising Action In Rare Kidney Disease ↗

October 02, 2023

Novartis AG (NYSE: NVS) announced topline results from the pre-specified interim analysis of the Phase 3 APPLAUSE-IgAN study at nine months of iptacopan, an investigational factor B inhibitor targeting...

Via Benzinga

Cardiol Therapeutics 76% YTD Gain Is A Bullish Signal Ahead Of Expected Phase III Trial Announcements ($CRDL)

October 02, 2023

Via AB Newswire

Topics Death

Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer ↗

September 29, 2023

Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies...

Via Benzinga

Allakos' Antibodies For Chronic Skin Conditions, Analyst Sees Over 400% Stock Upside ↗

September 27, 2023

JMP Securities initiated coverage on Allakos Inc (NASDAQ: ALLK), noting novel monoclonal antibodies targeting Siglec (sialic acid immunoglobulin-like lectin) receptors on immune cells that are drivers...

Via Benzinga

Ionis-Roche Join Forces To Compete In Neurodegenerative Disease Space, Analyst Sees Short-Term Challenges ↗

September 27, 2023

Ionis Pharmaceuticals Inc (NASDAQ: IONS) entered an agreement with Roche Holdings AG (OTC: RHHBY

Via Benzinga

Health Insurer Centene Streamlines - Plans Massive Layoffs To Cut Costs: Report ↗

September 27, 2023

Centene Corporation (NYSE: CNC) is reportedly laying off about 3% of its workforce as the health insurer plans to cut expenditures and accelerate profits over the years.

Via Benzinga

Topics Workforce

Benzinga's Top Ratings Upgrades, Downgrades For September 25, 2023 ↗

September 25, 2023

Via Benzinga

Amazon Invests $4B In ChatGPT Competitor, Hollywood Writers Accept Tentative Deal, ChatGPT Challenges Siri And Alexa With Introduction Of Verbal Responses: Today's Top Stories ↗

September 25, 2023

Benzinga

Via Benzinga

Novartis Sandoz Prepares For Public Debut With Strong Sales Record And Plans for New Biologic Drugs ↗

September 25, 2023

Novartis AG (NYSE: NVS) confirmed its plans for a 100% spin-off of the Sandoz business on October 4 after shareholders approved it

Via Benzinga

Are Gene Therapy Stocks The Market's Next Big Winners?

September 25, 2023

Biotechs Sarepta and BioMarin are among companies advancing cutting-edge gene therapies, although those treatments can come with a $2 million or more price.

Via MarketBeat

Topics Artificial Intelligence

Novartis Precision Cancer Therapy Hits Primary Goal In Rare Type Of Pancreatic Cancer ↗

September 25, 2023

Novartis AG (NYSE: NVS) released topline data from the Phase 3 NETTER-2 trial with Lutathera, a radioligand therapy (RLT) for advanced gastroenteropancreatic

Via Benzinga

Week In Review: Everest Acquires Novel Autoimmune Therapy In $132 Million Agreement ↗

September 23, 2023

Shanghai Everest Medicines acquired China/Asian rights to a novel therapy for autoimmune diseases from Kezar Life Sciences of South San Francisco in a deal worth $132.5 million. The company will make...

Via Talk Markets

AI To Revolutionize Clinical Trials And Diagnostics ↗

September 22, 2023

With the help of technology, the pharmaceutical industry is gaining new insights that are fueling the development of next generation of drugs while also speeding up clinical trials and improving...

Via Benzinga

Topics Artificial Intelligence

From Years to Months: How AI is Shaping the Landscape of Clinical Trials ↗

September 22, 2023

Pharmaceutical companies are harnessing artificial intelligence (AI) to speed up the traditionally arduous process of clinical trials, potentially saving both time and significant sums of money. These...

Via Benzinga

Topics Artificial Intelligence

Preventable Vaccines Market May See a Big Move : AstraZeneca, GlaxoSmithKline, Merck

September 19, 2023

Stay up-to-date with Preventable Vaccines Market research offered by AMA Research. Check how key trends and emerging drivers are shaping this industry growth.

Via SBWire

Amazon Poaches Microsoft's Product Chief, Google And DoD Team Up For AI-Powered Microscope To Identify Cancer, Rocket Lab's 41st Mission Succumbed To Technical Issues: Today's Top Stories ↗

September 19, 2023

Bloomberg

Via Benzinga

Chinese Drugmaker BeiGene And Novartis Move Out From Second Cancer Drug Pact ↗

September 19, 2023

BeiGene Ltd (NASDAQ: BGNE) said it would regain rights to develop, manufacture, and commercialize Tevimbra (tislelizumab), its cancer drug, from Novartis AG (NYSE: NVS).

Via Benzinga

AMC Stock Alert: Adam Aron Teases New Chocolate, Wine Brands for AMC ↗

September 15, 2023

AMC Entertainment (AMC) stock is a hot topic on Friday after the movie theater chain's CEO teased that new products are on the way.

Via InvestorPlace

Why Is Canopy Growth (CGC) Stock Up 14% Today? ↗

September 15, 2023

Canopy Growth (CGC) stock is rising higher on Friday after the cannabis company announced it won't fund BioSteel Sports Nutrition any longer.

Via InvestorPlace

Topics Cannabis

< Previous 1 2

...

24 25 26 27 28 29 30 31 32

...

59 60 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.